Age-related changes of the immune system leading to hyporesponsiveness; a major player and predictor for biological behaviour of metastasized melanoma?

Age-related changes of the immune system leading to hyporesponsiveness; a major player and predictor for biological behaviour of metastasized melanoma? - Aging immune system in melanoma patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43667

Enrollment

Registered

2012-04-03

Start date

2012-04-16

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastasized melanoma skin cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: > 18 years of age informed consent metastasized melanoma After treatment

Exclusion criteria

Exclusion criteria: severe anemia (Hb

Design outcomes

Primary

Measure	Time frame
To study the frequencies and differentiation status of CD4 and CD8 T cell populations (Tnaive, TCM, TEM, TEMRA) in young (18-50) and old (> 65) treatment naive metastasized melanoma patients at baseline and after treatment. In addition, the frequencies and differentiation of Treg in these two age groups will be assessed.	—

Secondary

Measure	Time frame
To study the presence of markers of the immune risk phenotype in patients (e.g. CD4/CD8-ratio, CMV-status). To study markers of immune senescence (e.g. CD27, CD28) and exhaustion (e.g. PD1, CTLA-4). Furthermore, this study increases our understanding of the pathophysiology of behaviour and development of melanoma in elderly and young pateints.	—

Countries

Netherlands

Outcome results